ClinicalTrials.gov
public full text
Public Domain
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
Vizimpro will be approved for the treatment of EGFR NSLCL 1L in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS. Post marketing surveillance is required to determine any problems or questions associated with Vizimpro after marketing in Korea, with regard to the following clauses under conditions of general clinical practice. Therefore, through this study, effectiveness and safety of Vizimpro will be observed.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Korean Regulatory Post Marketing Surveillance for Somavert#837412
- Korea Comirnaty Post-marketing Surveillance#1126077
- Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients#1150184
- Study Investigating Rapamune For Post-Marketing Surveillance#1124988
- Regorafenib Post-marketing Surveillance in Japan#1095971
Record · ID 1007760
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive